MDGL · ISSUER CIK 1157601
MADRIGAL PHARMACEUTICALS, INC.
Between Aug 1, 2026 and Oct 29, 2026, 3 MADRIGAL PHARMACEUTICALS, INC. insiders reported $0.00 of open-market purchases and $6.6M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$6.6MInsider selling
−$6.6MNet open-market
Sep 11, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 202616:57 | Sep 11, 2026from Sep 9, 2026 | MDGL | President and CEO, Director | S · Sell10b5-1 | $538.65 | −11,583 | 197,746 | -6% | −$6.2M | ||
| Aug 20, 202616:20 | Aug 17, 2026 | MDGL | General Counsel | S · Sell | $514.97 | −664 | 11,474 | -5% | −$342K | ||
| Aug 18, 202617:10 | Aug 15, 2026 | MDGL | Director | A · Grant | — | +647 | 647 | New | — |